Unleashing innovative cross-organ fibrosis therapies by harnessing the omics revolution
Explore this paper's citation graph
Summary
The current understanding of fibrogenic mechanisms, the progress and limitations of omics approaches in the identification of novel fibrotic pathways, and advances in therapeutic modalities are described that all together have the potential to unleash innovative cross-organ antifibrotic therapies.
- Type
- article
- Published
- 2026-07-08
- Cited by
- 0
- References
- 207
- Access
- Open access
- OpenAlex
- https://openalex.org/W7163813380
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:289115641
Keywords
Omics, Identification (biology), Therapeutic modalities, Fibrosis, Modalities
References
- Yolk Sac Macrophages, Fetal Liver, and Adult Monocytes Can Colonize an Empty Niche and Develop into Functional Tissue-Resident Macrophages.
- Heterogeneous fibroblasts underlie age-dependent tertiary lymphoid tissues in the kidney.
- Fibroblast‐specific integrin‐alpha V differentially regulates type 17 and type 2 driven inflammation and fibrosis
- Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease
- ER stress induces NLRP3 inflammasome activation and hepatocyte death
- Liver Fibrosis, but no Other Histologic Features, Associates with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
- Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies.
- Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis.
- Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
- IL-17 signaling in inflammatory cells, Kupffer cells and Hepatic Stellate cells exacerbates liver fibrosis
- Platelets in Inflammation: Regulation of Leukocyte Activities and Vascular Repair
- IL-17 and GM-CSF Expression Are Antagonistically Regulated by Human T Helper Cells
- Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study
- Diverse Roles of Invariant Natural Killer T Cells in Liver Injury and Fibrosis Induced by Carbon Tetrachloride
- Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
- Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent
- Selective αv integrin depletion identifies a core, targetable molecular pathway that regulates fibrosis across solid organs
- Adult-onset pulmonary fibrosis caused by mutations in telomerase
- IL-17A Enhances the Expression of Pro-fibrotic Genes through Upregulation of the TGF-β Receptor on Hepatic Stellate Cells in a JNK-dependent Manner
- Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE
Cited by
No citing papers recorded for this paper.
Related papers
No related papers recorded.